easysep human cord blood cd34 positive selection kit ii  (STEMCELL Technologies Inc)

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

doi: 10.1016/j.omtm.2025.101487

Figure Lengend Snippet: NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

Article Snippet: Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896).

Techniques: Derivative Assay, Comparison

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

doi: 10.1016/j.omtm.2025.101487

Figure Lengend Snippet: NSG-Quad mice support the development of human myeloid cells (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood of NSG-Quad +/− mice (heterozygous M-CSF, n = 24) and NSG-Quad +/+ mice (homozygous M-CSF, n = 9) at 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG-Quad +/− mice ( n = 24) and NSG-Quad +/+ mice ( n = 9) 10–15 weeks post-engraftment. (C) Percentage of human immune cell subsets in the blood of NSG-Quad +/− and NSG-Quad +/+ mice 10–15 weeks post-engraftment (data from B). (D) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (E) Human immune cell composition in the blood of NSGS ( n = 11) and NSG-Quad mice ( n = 25) 10–15 weeks post-engraftment. (F) Percentage of human immune cell subsets in the blood of NSGS and NSG-Quad mice 10–15 weeks post-engraftment (data from E). Data are shown as mean ± SEM. p values were calculated using two-tailed, unpaired Student’s t test (A), two-way ANOVA with Tukey’s multiple comparison test (D) and two-tailed, unpaired Mann-Whitney U test (C, F). ∗ p < 0.05, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

Article Snippet: Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896).

Techniques: Derivative Assay, Two Tailed Test, Comparison, MANN-WHITNEY

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

doi: 10.1016/j.omtm.2025.101487

Figure Lengend Snippet: NSG-Quad mice promote the development of tumor-infiltrating human macrophages (A) Tumor growth curves in NSG ( n = 9), NSG-Quad ( n = 12), and MISTRG-6 mice ( n = 15) engrafted with SW480 CRC cells and in NSG ( n = 10), NSG-Quad ( n = 4), and MISTRG-6 mice ( n = 14) engrafted with HCT116 CRC cells. (B) Frequency of hCD45 + cells in the tumor of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment). (C) Human immune cell composition in the blood of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment; data from G). (D) Human immune cell composition in the tumor xenografts of NSG ( n = 9, SW480; n = 10, HCT116), NSG-Quad ( n = 10, SW480; n = 3, HCT116), and MISTRG-6 mice ( n = 15, SW480; n = 12, HCT116). (E) Representative IHC pictures show SW480 CRC-infiltrating human CD68 + macrophages in NSG, NSG-Quad, and MISTRG-6 humanized mice. Scale bar: 50 μm. (F) Frequency of human CD68 + macrophages in CRC xenografts of NSG ( n = 11), NSG-Quad ( n = 7), and MISTRG-6 mice ( n = 15) analyzed by IHC. (G) Frequency of CD86 + (M1-like) and CD163 + (M2-like) human CD14 + monocytes in SW480 and HCT116 CRC xenografts of NSG-Quad ( n = 13) and MISTRG-6 mice ( n = 17). (H) Composition of the human CD33 + CD66b − myeloid cell population based on the expression of CD14, CD16, and HLA-DR in SW480 CRC xenografts of NSG-Quad ( n = 8) and MISTRG-6 ( n = 3) mice. Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (G) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896).

Techniques: Derivative Assay, Expressing, Comparison